Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Northern Trust Corp raised its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 710,321 shares of the company’s stock after buying an additional 142,578 shares during the quarter. Northern Trust Corp owned 1.32% of Fulcrum Therapeutics worth $3,339,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. lifted its holdings in Fulcrum Therapeutics by 50.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock worth $14,100,000 after acquiring an additional 1,000,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Fulcrum Therapeutics by 176.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock worth $1,728,000 after buying an additional 234,810 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Fulcrum Therapeutics during the fourth quarter valued at about $1,002,000. ADAR1 Capital Management LLC increased its stake in Fulcrum Therapeutics by 177.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 196,248 shares of the company’s stock worth $922,000 after acquiring an additional 125,446 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after buying an additional 3,126 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on FULC. Leerink Partners raised shares of Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $4.00 to $12.00 in a research note on Friday. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price target on the stock in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.83.

Fulcrum Therapeutics Price Performance

FULC stock opened at $6.44 on Friday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $10.13. The company has a market capitalization of $347.62 million, a price-to-earnings ratio of -20.77 and a beta of 2.29. The business has a 50 day simple moving average of $4.03 and a two-hundred day simple moving average of $3.91.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. Sell-side analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.